Direkt zum Inhalt
Merck

Fortfahren mit

07-374

Anti-phospho-KDR/Flk-1/VEGFR2 (Tyr1214) Antibody

Upstate®, from rabbit

Anmelden zur Ansicht der Organisations- und Vertragspreise.

Größe auswählen

Ansicht ändern
PackungsgrößeSKUVerfügbarkeitPreis
200 μg
Warenkorb auf Verfügbarkeit prüfen
€ 361,00

Über diesen Artikel

UNSPSC Code:
12352203
NACRES:
NA.41
eCl@ss:
32160702
Clone:
polyclonal
Species reactivity:
mouse, human
Application:
WB
Citations:
14

€ 361,00


Warenkorb auf Verfügbarkeit prüfen

Großbestellung anfragen
Technischer Dienst
Benötigen Sie Hilfe? Unser Team von erfahrenen Wissenschaftlern ist für Sie da.
Unterstützung erhalten


biological source

rabbit

Quality Level

antibody form

purified antibody

antibody product type

primary antibodies

clone

polyclonal

species reactivity

mouse, human

manufacturer/tradename

Upstate®

technique(s)

western blot: suitable

isotype

IgG

NCBI accession no.

UniProt accession no.

shipped in

dry ice

target post-translational modification

phosphorylation (pTyr1214)

Gene Information

human ... KDR(3791)

General description

200-230 kDa

Immunogen

(...FHpYDN...) in which pY corresponds to phosphorylated tyrosine at residue 1214 of human KDR/VEGFR2. Tyr1214 of human KDR corresponds to Tyr1212 in the mouse protein.

Application

Anti-phospho-KDR/Flk-1/VEGFR2 (Tyr1214) Antibody detects level of phospho-KDR/Flk-1/VEGFR2 (Tyr1214) & has been published & validated for use in WB.
Research Category
Signaling
Research Sub Category
Growth Factors & Receptors

Biochem/physiol Actions

phospho-KDR/VEGFR2 (Tyr1214)

Physical form

0.1M Tris-glycine, pH 7.4, 0.15M NaCl,0.05% sodium azide before the addition of glycerol to 30%
Format: Purified
Protein A purified

Preparation Note

2 years at -20°C

Analysis Note

routinely evaluated by immunoblot RIPA lysates from porcine aortic endothelial cells expressing human CSF-1R/murineVEGFR-2 chimera

Legal Information

UPSTATE is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Ähnliche Artikel vergleichen

Vollständigen Vergleich anzeigen

Unterschiede anzeigen

1 of 1

Dieser Artikel
07-81904-89407-278
species reactivity

mouse, human

species reactivity

human

species reactivity

mouse, human

species reactivity

human, mouse

antibody form

purified antibody

antibody form

affinity isolated antibody

antibody form

culture supernatant

antibody form

purified antibody

clone

polyclonal

clone

polyclonal

clone

D1W, monoclonal

clone

polyclonal

biological source

rabbit

biological source

rabbit

biological source

rabbit

biological source

rabbit

shipped in

dry ice

shipped in

dry ice

shipped in

dry ice

shipped in

dry ice

technique(s)

western blot: suitable

technique(s)

western blot: suitable

technique(s)

western blot: suitable

technique(s)

western blot: suitable


Still not finding the right product?

Probieren Sie unser Produkt-Auswahlhilfe, um Ihre Auswahl einzugrenzen


Lagerklasse

10 - Combustible liquids

wgk

WGK 1



Analysenzertifikate (COA)

Suchen Sie nach Analysenzertifikate (COA), indem Sie die Lot-/Chargennummer des Produkts eingeben. Lot- und Chargennummern sind auf dem Produktetikett hinter den Wörtern ‘Lot’ oder ‘Batch’ (Lot oder Charge) zu finden.

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen



Substitution of C-terminus of VEGFR-2 with VEGFR-1 promotes VEGFR-1 activation and endothelial cell proliferation.
Meyer, Rosana D, et al.
Oncogene, 23, 5523-5531 (2004)
Michael J Donovan et al.
European journal of cancer (Oxford, England : 1990), 45(8), 1518-1526 (2009-03-11)
To identify clinical and biometric features associated with overall survival of patients with advanced refractory non-small-cell lung cancer (NSCLC) treated with gefitinib. One hundred and nine diagnostic NSCLC samples were analysed for EGFR mutation status, EGFR immunohistochemistry, histologic morphometry and
Phosphorylation of Akt and ERK1/2 is required for VEGF-A/VEGFR2-induced proliferation and migration of lymphatic endothelium.
Dellinger, MT; Brekken, RA
Testing null